Journal Article

Use of a T Cell–Based Assay for Monitoring Efficacy of Antituberculosis Therapy

Stefania Carrara, Donatella Vincenti, Nicola Petrosillo, Massimo Amicosante, Enrico Girardi and Delia Goletti

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue 5, pages 754-756
Published in print March 2004 | ISSN: 1058-4838
Published online March 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/381754
Use of a T Cell–Based Assay for Monitoring Efficacy of Antituberculosis Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Monitoring the efficacy of antituberculosis therapy is crucial both for the individual patient and for better control of the spread of tuberculosis. We studied 18 patients with microbiologically confirmed tuberculosis, both at the time of diagnosis and 3 months after they started therapy, using an in vitro assay that detects T cell–mediated interferon-γ response to selected peptides of Mycobacterium tuberculosis–specific early secretory antigenic target 6 (ESAT-6) protein. All patients had positive results at diagnosis; however, 3 months later, the response to ESAT-6 peptides was still detectable only in the 5 patients with microbiological isolation and/or absence of clinical improvement after treatment. On the basis of these data, we conclude that our assay is a useful tool in monitoring the efficacy of antituberculosis therapy.

Journal Article.  2142 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.